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3D printing technique has been utilised to develop novel and complex drug delivery systems that 
are almost impossible to produce by employing conventional formulation techniques. For example, 
this technique may be employed to produce tablets or fast dissolving oral films (FDFs) with 
multilayers of active ingredients, which are personalised to patient’s needs. In this article, we 
compared the production of FDFs by 3D printing to conventional methods such as solvent casting. 
Then, we evaluated the need for novel methods of producing fast dissolving oral films; and why 
3D printing may be able to meet the short falls of FDF production. The challenges of producing 
3D printed FDFs are identified at commercial scale by referring to the identification of suitable 
materials, hardware, quality control tests and Process Analytical Technology. In this paper we 
discuss that the FDF market will grow to more than $1.3 billion per annum in next few years and 
3D printing of FDFs may share part of this market. Although, companies are continuing to invest 
in technologies which provide alternatives to standard drug delivery systems, the market for thin 
film products is already well established. Market entry for a new technology such as 3D printing 
of FDFs will, therefore, be hard, unless, this technology proves to be a game changer. A few 
approaches are suggested in this paper.  
 










Three dimensional printing (3DP) has been employed for the development of novel pharmaceutical 
dosage forms. These include tablets,[1, 2] capsules,[3] nose patches,[4] filaments,[5] core-shell 
tablets,[6] gastero-floating tablets,[7] hollow cylinders,[8] dual compartmental dosage units,[9] 
multi-compartment capsular devices,[10] orodispersible films,[11] fast dissolving oral films,[12] 
and liquid capsules.[13] 3DP contributes to more end-stage personalisation of solid dosage 
forms.[14-18] One aspect of personalised medicine is the move away from the concept of ‘one-
size fits-all’ to treatment of patients meeting their particular needs. This provides better 
management of patients’ health and achieving desired therapies with the best therapeutic 
outcomes. In particular, 3DP allows the adjustment of a drug dose based on patient’s health state. 
Additionally, 3DP permits the combination of more than one active pharmaceutical ingredient 
(API) in tablets to produce polypills and reduce the number of administered tablets, which would 
improve patient compliance.[19, 20]  
Although 3DP appears to produce one dosage form at-a-time for each individual, this technique 
has been applied at industrial scale. The Food and Drug Administration (FDA) approved Spritam® 
(brand name of Levetiracetam) as a 3D-printed tablet for the treatment of epilepsy. The main 
advantage of Spritam is instantaneous disintegration over few seconds, which cannot be achieved 
by conventional tablet formulations. 
Fast dissolving oral films (FDFs) are commonly used in the administration of drugs to paediatric 
and geriatric patient populations, where the difficulty for swallowing solid oral dosage forms is 
eliminated. This approach can also be useful for patients who have swallowing difficulties 
(dysphagia). It is estimated that approximately one in 25 adults has swallowing problems. [21] In 
addition, elderly and children are more prone to swallowing difficulties. Some patients with 
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dysphagia have problems swallowing certain foods or liquids, while others can't swallow at all. 
There are two classifications of dysphagia: 
A. Oropharyngeal dysphagia refers to difficulty in the passage of liquids or food from the 
mouth to the oesophagus. 
B. Oesophageal dysphagia refers to difficulty with the passage of food through the 
oesophagus. 
FDFs can be used for both standard oral drug delivery where the active ingredient is swallowed by 
the patient and absorbed in the gut, or for buccal drug delivery where the active ingredient is 
absorbed within the mouth. Buccal drug delivery is a promising area for continued research with 
the aim of systemic delivery of orally inefficient drugs as well as a feasible and attractive 
alternative for non-invasive delivery of potent peptide and protein drug molecules.[22]  
The market for FDFs has been under development for at least two decades, and it is well 
established in certain indications, in particular, over-the-counter. FDFs are manufactured by hot-
melt extrusion or solvent-casting methods.[23-26] Although the solvent-casting process is popular, 
the application of hot-melt extrusion process is growing, this is due to its solvent-free, continuous 
production, and resulting in less chance of drug instability. Fused-deposition modelling 3D 
printing (FDM-3DP)-described in the following-is closer to hot-melt extrusion method. Previous 
works have shown the feasibility of producing FDF by 3DP.[11, 12, 27] The aim of this article is 
to explore production of FDF at the industrial scale by 3DP and identify challenges to achieve this 
goal. This is important, as companies are continuing to invest in technologies which provide 
alternatives to standard drug delivery systems. While, the market for thin film products is already 
well established, market entry for a new technology such as 3D printing of FDFs will have to 
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overcome barriers to entry, unless, this technology proves to be a game changer, and in this paper 
a few approaches are suggested. 
2. Principles of 3DP 
In 1971, Wyn Kelly Swainson filed a patent for producing three-dimensional figure product,[28] 
followed by Charles W. Hull, who filed a patent for 3D printing by stereolithography in 1984.[29] 
Generally 3DP processes start with a computer-aided design (CAD) model or a digital scan. The 
CAD models are produced by computer software such as SolidWorks (Dassault Systèmes) as 
shown in Figure 1A. Then this is converted into the Standard Tessellation Language (STL) format, 
which is modified into thin cross sections by a slicing software (Figure 1B). This software also 
allows to adjust other 3DP parameters such as type and colour of 3DP material (Figure 1C), infill 
percentage and thickness of each layer (Figure 1D), 3DP printing extruder temperature and build-
plate temperature (Figure 1E), and the speed of printing (Figure 1F). The thickness of each layer 
ranges from 500 nm [30] to 2500 µm.[31] This allows the creation of highly personalised and 
detailed 3D physical objects from digital designs. Then, a 3D printer conducts the printing process, 
which usually prints or forms (laser curing) a 2D pattern on a printer build-plate or in a liquid [32]. 
Following completion of this layer, the printer makes another layer (usually on top of that). This 




Figure 1: Digital steps in 3DP: A) CAD model is produced by software, B) Software to slice the CAD model to thins sections, C) 
Adjusting type and colour of filament in FDM 3DP, D) Adjusting infill percentage and layer height, E) Adjusting temperature of extruder 
in FDM printing and the temperature of build-plate, F) Adjusting the speed of printing. 
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3. Types of 3DP 
There are three types of 3DP that widely used for the manufacture of solid dosage forms. These 
are explained in the following. 
3.1 Inkjet 3DP  
Inkjet method produces uniform droplets from an inkjet device. [33] The first application of inkjet 
3DP was published by Katstra et al. 2000 to produce tablets.[34] In this method the 3DP was 
composed of spreading a thin layer of powder over a piston plate. Then a liquid binder solution 
was passed through a nozzle, which was rastered back and forth over the powder bed, which 
allowed printing droplets on the powder and binding powder particles. This generated a 2D pattern. 
Then the piston was lowered by a fixed distance and another powder layer was spread over the 
previous layer and the process was repeated. It appears that a continuous inkjet printing mode was 
utilised in the work, as the droplets were estimated to be 80-90 µm from a 45 µm nozzle. [33] 
Clearly this method would require drying manufactured tablets, which could delay production 
process and increase costs. This inkjet method is the basis of producing Spirtam tablets (the 
Aprecia’s patented ZipDose ®Technology). In a similar approach, Shi et al. 2019 reported the 
application of Z Corp 3D printer in the manufacture of tablets with 10-15 mm diameter.[35] In this 
technique, an inkjet printing head moved across a bed of powder containing mainly CaSO4, which 
precisely deposited a liquid binding material containing 5-fluorouracil, PEG and Soluplus in the 
shape of tablet. A fresh layer of powder was spread across the top of the model, and the process 
was repeated. When the tablet was complete, unbound powder was removed.[35] Increasing the 
tablet diameter increased the dissolution rate of the API. 
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Inkjet printing has also been employed for the manufacturing of tablets with internal honeycomb 
structure to control drug release.[1] A molten (90C) mixture of beeswax and drug was fed to a 
piezoelectric inkjet nozzle, which was operated under drop-on-demand mode. The nozzle diameter 
was 35 µm. These tablets did not need a drying process, which accelerates the production process. 
In addition, the operating temperature is relatively low (90ºC) compared to fused deposition 
modelling (165-190ºC [12]), which makes this approach more attractive. Finally, this method does 
not require high molecular-weight polymers, which would be useful for the 3DP of fast dissolving 
oral films.[12] Buanz  et al. applied thermal inkjet printing to deposit droplets of salbutamol 
solution on oral films made of potato starch.[36] This method was useful for depositing a single 
layer of drug solution; as multiple layers damaged the films, which would be expected by 
considering hygroscopic nature of the starch films. The same approach was applied to deposit 
warfarin on hydroxypropyl methylcellulose (HPMC) films.[37] On the other hand, Eleftheriadis 
et al. 2018 applied thermal inkjet printing to deposit diclofenac sodium solution (containing water 
and ethanol) on Décor Paper Plus edible sugar sheets in multiple prints; and they found that the 
sugar sheets maintained their integrity up to 9 repeated prints.[38] Janßen et al. 2013 applied 
Flexographic printing to print on orodispersible films. Although this is not an inkjet printing, it is 
a common technique for industrial printing onto surfaces such as capsule shells.[39] Genina  et al 
2012 combined inkjet printing and Flexographic printing to produce papers containing APIs 
(deposited by inkjet printing) and coated by polymers (using Flexographic printing).[40] In another 
approach, Kollamaram  et. al. 2018 utilized drop-on-demand inkjet printing to deposit paracetamol 
and indomethacin on hydroxypropyl methylcellulose films. The inkjet nozzles had diameters in 
the range of 150-300 µm due to high viscosity of the ink solutions. The films contained average 
amounts of 447 µg of paracetamol and 703.1µg of indomethacin.[41] The investigators avoided 
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using aqueous solutions in the inks to prevent disintegration of the films. This is important as, the 
surface roughness of the films may have a negative impact on patient experience. Planchette et al 
2016 showed that deposition of drug solutions on orodispersible films by inkjet method could be 
optimised to avoid this drawback.[42] Interestingly, Buanz  et al 2015 found that inkjet-printed 
films did not exhibit drug crystallisation in the films, while solvent-casting method encountered 
this problem.[43] To achieve product traceability and combat drug counterfeiting, Trenfield  et. 
al. 2019 combined inkjet printing and 3D printed tablets. The inkjet printing was utilized to deposit 
QR codes on 3D printed tablets. The ink was made of methylparaben (20% w/v), Eudragit RS100 
(10% w/v) and sodium benzoate (2% w/v) in a mixture of ethylmethylketone, acetone and 
methanol (50:20:30).[44] In a recent work, Thabet et al. 2018 reported a continuous production of 
orodispersible films by inkjet method.[45] Initially a roll of orodispersible film was made as base-
film by a solvent casting method; and then a dye solution was printed on the base-film. The printed 
layers were produced in the drop-on-demand mode utilising an inkjet head with 30 µm nozzle 
diameter. This approach allowed producing multi-layered films. As it would be expected, a drying 
process was involved to convert the wet film into a dried film, for both the base-film and printed-
film. The printed films disintegrated in 15 s.[45]  
To increase the loading capacity of inkjet printed solid dosage forms, Iftimi et al. 2019 applied 
inkjet printing on pharmaceutical solid foams. They found that the plasticised HPMC foams had a 
superior absorption capacity and fast penetration speed for different solvents due to the open cell 
pore structure and higher porosity as compared to nonplasticised additive-free foams.[46] To 
achieve foams with different porosity, methods were applied such as freeze-drying, vacuum oven 
drying and drying at room temperature.[46] The surfaces of foams changed after inkjet printing of 
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the API-containing ink, due to a partial dissolution and/swelling by water-based ink during 
printing, however, the foams were able to maintain integrity up to 35 repeated prints.[46]  
 3.2. Fused Deposition Modelling 
Fused deposition modelling has been applied widely in manufacturing of novel pharmaceutical 
dosage forms.[47-55] Filaments (typically 1.75-3 mm) are feedstock of conventional FDM 3D 
printers. In these printers, the filament passes through a tubing system and rotating pulleys/gears 
in the 3D printer head, which melts and extrudes the filament through a narrow nozzle (typically 
0.4 mm diameter). The molten filament is deposited on a platform according to the design created 
using the slicer software. The rastered back and forth movement of the printer head deposits the 
molten material side-by-side, and the z-axis movement of the platform deposits the molten 
filament layer-by-layer. The molten-state of the filament fuses the layers. This process is repeated 
until the object is fully materialised. FDM 3D printers can produce objects with homogenous drug 
distribution,[56] and reproducible dimensions, in particular when filaments are used with uniform 
diameters (low diameter tolerance).[49] Polylactic acid (PLA), polyvinyl alcohol (PVA) and 
acrylonitrile butadiene styrene (ABS) are the main polymers used in FDM-3DP.[32] To ensure 
that each deposited layer can hold another layer on the top, the melting point of the filaments 
should be much higher than the printing environment temperature. The typical melting 
temperatures are above 100ºC. Therefore, the filaments should be thermally stable, non-volatile 
and non-aerosolising.[57] The API usually is incorporated in the filament, hence, the stability of 
the API during 3DP is essential. The low cost of FDM printers has been the main reason for the 
wide application of FDM 3DP in pharmaceutical dosage forms.  
In the FDM 3DP the drug is loaded into the filament either by extrusion method or absorption. 
Pietrzak et al. 2015 employed a twin-screw extruder operating at 130C to produce a filament of 
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theophylline and Eudragit.[47] Similarly, Maroni et al 2017 used a twin-screw extruder (Haake™ 
MiniLab II, Thermo Scientific, US-WI) equipped with counter-rotating screws, to produce 
filaments made of HPMC, Kollicoat® IR (KIR), and hydroxypropyl methyl cellulose acetate 
succinate (HPMAS) at operating temperature of 165C.[5, 10] This research group produced 
filaments of hydroxypropyl cellulose (HPC) at slightly less temperature 150C.[3] Also, 
Gioumouxouzis et al. 2017 mixed hydrochlorothiazide, PVA and mannitol to create a homogenous 
mixture, which was fed to Filabot Original® single-screw hot-melt extruder operating at 170C.[8] 
In a different approach, PVA and Aripiprazole was mixed in ethanol to ensure good drug content 
uniformity in the extruded filament. The mixture was dried at 70C for six hours to prevent 
formation of air bubbles during extrusion. The filament was produced using Noztek® Pro filament 
extruder at 172C.[11] To reduce the operating temperature of the hot melt extrusion, Okwuosa et 
al. 2016 incorporated polyvinylpyrrolidone (PVP) into the filament formulation, which reduced 
the operating temperature down to 90-100C.[58] While, this research group also found that 
Eudragit EPO can be extruded at 90C.[13] Similarly, Ehtezazi  et al. 2018 employed polyethylene 
oxide to reduce the operating temperature down to 60C.[12] On the other hand, Goyanes et al. 
2015 immersed PVA filament in a beaker containing ethanol where the drug (5-ASA or 4-ASA) 
was dispersed.[49] This was to absorb drug into the filament. It should be noted that filaments 
should have suitable strengths to withstand the stresses during printing. To achieve this, high 
molecular weight polymers will be required, at least 40 kDa,[58], or preferably greater than 100 
kDa.[12] A simplex centroid mixture design experiment may be applied to predict the best polymer 




3.3. 3D Based Extrusion Printing 
This is an example of direct-writing 3DP and has been applied for the formulation of tablets.[2, 
19, 60-62]. In this approach, a paste of drug and excipients is prepared and fed to cartridges such 
as syringes. Then the pasted is extruded through tips with nozzle diameter of 500 µm.[19] Similar 
to the FDM, the paste is deposited on a platform according to the design created using the slicer 
software. The back and forth movement of the printer head deposits a thin layer of the paste and 
the z-axis movement of the platform deposits the paste layer-by-layer. After completion of the 
printed dosage form, the object is dried at temperatures such as 40C over 24 hrs, or lyophilised. 
It is evident that this technique of 3D printing does not require the formation of filament. However, 
a drying process is required to reduce the solvent residue, less than limits set by ICH 
guidelines.[19] 
A powder based extrusion 3DP has been used for printing of tablets. [63] This is another example 
of direct-ink writing 3DP, where the powder mixture containing drug and excipients is feed to the 
nozzle. The nozzle temperature is high enough (170C) to melt the powder mixture and leave a 
molten deposit on the printing platform. The advantage of this method is avoiding need for the 
formulation and preparation of filament. Zidan et al 2019 applied X-ray tomography to study 3D 
micro-extrusion printing technology; and they found presence of air pockets in the printing 
cartridges that were formed during packing the printing cartridges.[64] Although the produced 
tablets did not show any defects due to the air pockets, the risk of producing defective tablets was 
still there. As an advantage, 3D micro-extrusion printing method avoids exposing the drug and 
excipient molecules to high temperatures (FDM) or UV irradiation (UV-curing 3DP), but the paste 
formulation requires pressures between 0.5-4.5 bar to extrude from the nozzle. Hence, the paste 
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formulation should be optimised to allow consistent flow of the paste from the nozzle to achieve 
reproducible products.[64]  
4. Conventional Methods of Manufacturing Fast Dissolving Oral Films 
Fast dissolving oral films (FDFs) are thin films with the area of 5-20 cm2 containing an active 
ingredient. The fast dissolution/disintegration is achieved in water or saliva by water-soluble 
polymers. The fast dissolving feature would improve patient compliance.[65] Typically the 
loading dose of FDFs is less than 15 mg. The formulation contains a matrix polymer, plasticiser, 
taste masking agent, colour, and API. There are two methods that are widely used for the 
formulation of FDFs: solvent casting technique, and hot melt extrusion.[66] Other methods have 
been also reported in the literature such as semisolid casting, solid dispersion extrusion, rolling, 
[67] electrospinning, and electrospraying.[68] 
4.1. Solvent casting 
The solvent casting method is the most popular method for the manufacture of FDFs.[69-81] In 
this method, all the formulation components are dissolved/dispersed in an aqueous media. Then, 
the homogenate is cast over a flat and wide surface (usually glass) for drying to form a thin film. 
This is followed by peeling-off the film and cutting to desired sizes. Recently, Visser et al. 2017 
reported the formulation of bilayered FDFs. This was achieved by a double-casting method. 
Initially, the first layer of casting solution was cast using a casting height between 500 and 2000 
μm. The film layer was dried for 1.5–8 h at 30 °C and ambient relative humidity. After drying of 
the first layer, the second layer was cast and dried.[82] 
There are challenges when the formulation is scaled up from the small laboratory scale to industrial 
scale. The casting and drying processes are the critical steps. Then, the optimization of casting 
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speed and drying time are important from the commercial point of view. As the thickness of wet 
strip cast, the rheological and physicochemical properties of the cast solution affect the drying 
speed.[83, 84] These limit the scale-up process, which could affect the final thickness of the dried 
strip. Furthermore, the selection of solvents depends on the solubility of the API, its stability in 
the solvents and its heat sensitivity during the drying process. The suitable solvent for the API may 
affect the solubility of plasticiser and taste masking agents. It should be added that solvent residues 
should be determined in the FDFs according to ICH Q3C.[85] This document recommends 
acceptable amounts for residual solvents in pharmaceuticals for the safety of the patient. Also, it 
recommends the use of less toxic solvents; and describes solvent levels, which are considered to 
be toxicologically acceptable for some residual solvents. This document recommends avoiding 
using toxic solvents such as 1,2-Dichloroethane (Class I solvents). Solvents such as chloroform 
and dichloromethane are recommended for limited use (Class II solvents). According to this 
document, the residues of dichloromethane should be less than 600 ppm, and the residues for 
chloroform should be less than 60 ppm. Ideally, less toxic solvents (Class 3) should be used, where 
this is practical.[86] These include solvents such as acetone, ethanol, and ethyl ether. 
When FDFs are dried, they are cut into suitable shapes and sizes according to the required dosage. 
Sometimes, the companies roll and keep the uncut FDF batch, known as ‘rollstock’.[66] However, 
this should be avoided, as the properties of the product may change over the storage period, in 
particular it may absorb moisture from the environment.[83]  
The structured orodispersible film templates (SOFTs) have been developed by the solvent casting 
method. The SOFTs were developed to achieve a highly porous, drug free template for the 




4.2. Hot melt extrusion 
The hot melt extrusion (HME) is becoming a popular method.[23] In this approach, all the 
components are mixed and fed into a screw extruder, which is most widely accepted for 
pharmaceutical industry. The extruder operates at temperatures in the range of 40-180 ºC. [88-91] 
Then the molten mixture is introduced into a die system, which determines the shape of the 
film.[66] There are benefits to HME such as: lack of drying process, avoiding degradations in a 
solvent, and better product homogeneity.  
5. The Application of 3DP for the Manufacture of FDFs 
3DP or additive manufacturing has been applied in the formulation of FDFs or oral films. Jamróz  
et al. 2017 applied FDM 3DP to produce FDFs of aripiprazole.[11] As explained in the above, the 
API and PVA powder initially dispersed in ethanol to ensure a homogenous mixture, which was 
dried at 70ºC. The dried powder was fed to an extruder to produce filament at 172ºC. Although 
the manufactured filament was not smooth, it was possible to be used in FDM 3DP. The presence 
of air bubbles made the surface of the filament uneven. At this stage it is not clear the reason for 
the formation of air bubbles. As this has not been observed in other studies, then it is possible that 
residual ethanol was released at high temperature of extrusion. In addition, the filaments were 
brittle. On the other hand, PVA filaments had suitable mechanical properties in other studies. 
Therefore, it remains to be determined that whether aripiprazole itself or its fraction in the PVA 
caused undesired mechanical properties of the filaments. The dimensions of designed aripiprazole 
FDFs were 20×30×0.15 mm. During 3DP the adhesion of PVA film on the printer build-plate was 
an issue. The authors utilized BuildTak® adhesive and heated printer build-plate to overcome the 
problem. These adjustments are critical since the 3DP object had only one layer; and this must be 
defective-less. The authors compared 3DP FDFs with FDFs prepared by the solvent casting 
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method. As reported previously, crystals of aripiprazole was observed in the FDFs by the solvent 
casting method, while these were absent in 3DP FDFs. The FDFs disintegrated in the range of 
27.5-43.0 seconds. Incorporation of the API increased the disintegration time. The thickness of 
films prepared by solvent casting method was approximately 2 times smaller than 3DP films, but 
the disintegration time was only 5 s faster. 
Ehtezazi  et al. 2018 applied FDM 3DP for the formulation of multi-layered FDFs[12]. In the 
formulation PVA (Mw= 89-98 kDa) was used as powder to be mixed with paracetamol 
(acetaminophen). The filaments were manufactured by employing Noztek Pro Filament Extruder, 
operating at 130C. This was to ensure that a stiff paste would be extruded. This was reflected in 
the X-RD data that PVA crystals were present in the filament and to some degree in the film. The 
resulting filaments showed suitable strength for FDM 3DP. In this work another layer of taste 
masking agent was printed on the drug containing layer. A smooth filament was produced using 
strawberry powder and PEO (Mw=100 kDa). The printed films had thickness of greater than 197 
µm, which were thicker than FDFs reported by Jamróz  et al. 2017,[11] however, the disintegration 
time was similar in some formulations and much longer for tripled layer FDFs. As for Jamróz  et 
al. 2017 work [11], the adhesion of printed FDFs on the printer build-plate was a problem, which 
was rectified by using sticky masking blue tape (3M™). The FDFs were printed at 190C for PVA 
drug containing layer (similar to previous work [11]) and 160C for taste masking layer.  
In another work reported in 2018 by Musazzi  et al, a hot melt ram extrusion 3D printer was 
employed to produce FDFs.[27] In this method ,maltodextrin, glycerol, glycine, titanium dioxide 
and paracetamol were mixed and introduced into the chamber of piston, which was 
thermostatically set in the range of 30-200C. Using a ram, controlled amounts of the molten 
mixture were deposited on a mobile plate. The produced films had thickness in the range of 150-
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250 µm, with disintegration time in the range of 65-111 s, which was slightly longer than for 
previously reported FDM 3DP films. [11, 12] One of the main advantages of this approach is the 
elimination of the filament manufacturing process. Drug loading was 40%, which allowed to load 
up to 73.56 ± 3.90 mg of paracetamol, which is comparable to the loading of FDM 3DP films 
reported previously (91.12 ± 4.40 mg).[11] The hot melt ram extrusion 3D printer produced films 
at 85C, [27] which was much lower than the operating temperature of previous works (190C) 
that used PVA as the polymer.[11, 12] This is another main advantage of the hot melt ram extrusion 
3D printer, which would not compromise the stability of the active ingredient. About 80% of 
paracetamol was released within 6 minutes from FDFS produced by the hot melt ram extrusion 
3D printer.[27] While for FDFs produced by the FDM, the drug release rate was similar only to 
single layered FDFs, adding taste masking layer reduced the drug dissolution rate.[12] 
Interestingly, the drug release was faster for aripiprazole FDM 3DP films, compared to films made 
by the solvent casting method. The FDM 3DP films released about 90% of aripiprazole within 5 
minutes, while this was about 50% for FDFs made by the solvent casting method.[11] It should be 
noted that the principles of the hot melt ram extrusion 3D printer is similar to the regenHU 3D 
printer (regenHU, Fribourg, Switzerland, Figure 2), which was employed to produce paracetamol 









Table 2. Summary of some research work conducted on FDFs 
Polymers Manufacturing 
Method 
Drug Dose Film 
Thickness  
Reference 
Maltodextrins Solvent Casting Piroxicam a28.2 
mg 
204 µm [88] 
Maltodextrins Hot Melt 
Extrusion 
Piroxicam a27 229 µm [88] 
PVA 3D FDM Paracetamol b8.5 mg 298 µm [12] 
PEO 200 kDa 3D FDM Ibuprofen 27.1 
mg 
245 µm [12] 








Hypromellose E15 Solvent Casting Lercanidipine 
HCl 
25 mg 57.5 µm [92] 
HPMC (15 cps) Solvent Casting Granisetron 
Hydrochloride 
1 mg 67 µm [74] 
HPMC K4M Solvent Casting Piroxicam 10 mg 200 µm [93] 
PVA/PVP Electrospinning Piroxicam 1 mg 43 µm [94] 
Dextran and 
Maltodrextrin 
Solvent Casting Amphotericin B d0.3 mg 140 µM [95] 
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100 µM [96] 
HPMC Solvent Casting Captopril 10 mg 400 µm [97] 
Maltodextrins Solvent Casting eMelatonin  f3.4 mg 235 µm [98] 




4 mg 60-110 µm [99] 
HPMC Solvent Casting Diclofenac 
sodium 
20 mg 576 µm [100] 
Trehalose/pullulan Solvent Casting gTherapeutic 
Proteins  
0.8 mg 600 µm [22] 





90 µm [101] 





Solvent Casting Paracetamol i123 
mg 
189 µm [102] 
aBased on a 2×3 cm film size 
bDual layer film with one taste masking layer 
cWithout take masking layer 
dBased on 1×1 cm film 
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eMelatonin as free drug + lipid microparticles loaded with melatonin 
fBased on 30 mg FDF 
gLysozyme and β-galactosidase were considered in the study, but the application can be extended 
to insulin 
hDrug was loaded into mesoporous silica nanoparticles 
iBased on 2×3 cm film 
5.1. Critical Comparison between Conventional and 3D Printed FDFs 
The machinery is well established for industrial scale and continuous production of films by the 
solvent casting method. There are several suppliers in the market that can provide industrial scale 
film making equipment such as Harro Höfliger, Umang Pharmatech Pvt. Ltd, and Aligned 
Machinery. The machine evenly coats a layer of liquid material on the surface of a reel base roll. 
The solvent is evaporated and dried through drying channels. The film is collected after cooling in 
a roll. In addition, packaging machines have been developed that cut the film rolls into desired 
sizes and packed in pouches or sachets. 
On the other hand, 3D printers for mass production are about to enter to the market. A modular, 
automated FDM 3D printing system has been developed by the Stratasys Ltd with interconnected, 
high-throughput capabilities. This allows to achieve scalable volumes. Although currently 
machinery is not available commercially for the mass production of 3D printed FDFs, the 
technology is improving, and it appears in near future this aim will be achieved. 
For 3D printing of FDFs by the FDM, this would require the manufacture of filaments, which 
would allow feeding the material to the 3D printer. The formulation of the filament would require 
optimisation based on the drug and dose. Perhaps this would be equivalent to the manufacture of 
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slurry/solution for the production of FDFs by the solvent casting method. The use of filaments 
provides the possibility of continuous production by 3D printing. Although direct ink writing 3D 
printing by screw-fed method [103] may eliminate the use of filament in 3D printing of FDFs in a 
continuous mode for mass production, this approach would require its own optimisations. This 
includes suitable mixing of the powder in the printer head, formation of suitable molten paste at 
the tip of the printer nozzle permitting manufacture of a 3D object. 
Recrystallisation may occur by using the solvent casting method, [104, 105] which inadvertently 
can affect active ingredient homogeneity. While this is less likely to occur by employing 3D FDM, 
due to uniform distribution of drug molecules/particles within a polymer matrix.[12, 106] Using 
the solvent casting technique, the incorporation of a particulate API may alter mechanical strength 
of the FDF, [88] whereas 3D printing provides the opportunity to print the drug/taste masking layer 
as a separate layer on a support/drug load base.[19, 39, 107, 108]  
Both 3D FDM and solvent casting methods may require a new development of an FDF formulation 
for each API. However, these may be avoided by applying flexographic printing technology, as 
drug is printed on a base, [39] although a high drug dose may not be loaded on the film.  
Furthermore, 3D FDM provides easily both scale-up and scale-down of the process, than solvent 
casting method.[109] This is because 3D FDM allows to print FDFs in single units, the number of 
printed films can be adjusted according to the needs. While for the solvent casting method, scale-
up of the process requires suitable adjustments to ensure achieving homogenous mixtures with 
suitable viscosity to form a film.[105] Also, less cleaning may be required for the manufacture of 
FDFs by both 3D FDM and flexographic printing technology[39] than solvent casting method, as 
it may require cleaning homogeniser and tanks for manufacturing the casting mixture. It should be 
noted that cleaning of extruder will be required for 3D FDM, while cleaning the printer can be 
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achieved relatively easily. There is a potential risk of leachables and extractables from the plastic 
liner in the solvent casting method, [110] however, this may be minimised by the 3D FDM, when 
a metal printer bed is utilised. Finally, a range of doses can be realised by 3D FDM,[47, 106] by 
printing different layers, but this could be challenging by using a solvent casting method.[111]  
5.2. Characterization of 3D Printed FDFs 
There are several methods to characterize FDFDs,[112] which are also applicable for 3DP FDFs. 
These are explained in the following. 
 5.2.1. Tensile properties 
Tensile properties may be considered as tensile strength, elongation (strain), and Young’s modulus 
(elastic modulus). Tensile strength is defined as maximum stress applied at which the film or 
filament (if this is applicable) breaks. This test should be performed for both 3DP FDF and the 
filament. Tensile strength test is performed to measure the mechanical strength of films and 
filaments. A suitable mechanical strength of filament is required, to ensure withstanding the 
mechanical stress during printing. It can be calculated from applied load at the rupture point 
divided by the strip/filament cross-sectional area given in the equation below[113]: 
𝑇𝑒𝑛𝑠𝑖𝑙𝑒 𝑆𝑡𝑟𝑒𝑛𝑔𝑡ℎ =
𝐿𝑜𝑎𝑑 𝑎𝑡 𝐵𝑟𝑒𝑎𝑘𝑖𝑛𝑔 𝑃𝑜𝑖𝑛𝑡
𝐹𝑖𝑙𝑚 𝑊𝑖𝑑𝑡ℎ×𝐹𝑖𝑙𝑚 𝐿𝑒𝑛𝑔𝑡ℎ
        [1] 





× 100          [2] 
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Where L0 denotes initial length of the film and L depicts final length of the film after applying 
force. Typically, the tensile properties of FDFs are measured by employing a texture analyser [12, 
47, 88, 114, 115]. Tensile properties provide information about the integrity of the product while 
handled by the user or during packaging procedure. Tensile properties also reveal the interaction 
between plasticizer and polymer in the FDF, whether the polymer and plasticizer mix freely.[88] 
It has been suggested to calculated tear resistance of FDFS too.[112] 








             [4] 
Where  denotes the stress on the film and E is defined as strain.  
Maltodextrin FDFs (prepared by holt melt extrusion) showed tensile strength in the range of 1-7 
MPa, with %E of 92-559%, and Young’s modulus of 0.26-1.93 MPa, [88] while tensile strength 
of 10.7 ± 0.5 MPa has been reported for films prepared by solvent casting method.[116] The 
inclusion of nanoparticles increased tensile strength of FDFs prepared by the solvent casting 
method, but reduced film elongation when the film breaks.[117]  
5.2.2. Film flexibility 
The film flexibility is determined by bending the film over a shaft/mandrel and the film is 
examined for cracks over the area of the bend. The film is assumed flexible if no cracks are visible 
at a 5 times magnification.[88]  
5.2.3. Folding endurance 
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A film/strip is repeatedly folded until it breaks. It is stated as the number of folds at the breaking 
point. A film is considered structurally durable (having a good folding endurance number) if the 
folding endurance is in the range of 200-300; and the film is considered structurally acceptable 
(having an average film endurance number) if the folding endurance is less than 200 but the film 
withstands few folds. If the film is brittle, then it has poor folding endurance.[92]  
5.2.4. Morphology study 
The morphology of films or filaments are evaluated by Scanning Electron Microscopy (SEM) [11, 
12, 45, 118-120] and optical microscopy.[11, 120, 121] These evaluations allow to determine the 
smoothness of filament or film surfaces or small air bubbles intrusions into filaments or films. The 
SEM studies of film cross sections showed the formation of a network between the polymer and 
drug.[119]. The rough surface of films would affect acceptance of the film by the patient.[120]  
5.2.5. Swelling property 
Although measuring the swelling properties of FDFs has been suggested,[112] this would be more 
suitable for buccal films that are designed to adhere to the surface of mucosa in the oral 
cavity.[122] This is because FDFs are designed to disintegrate in the range of 5-60 seconds, and 
this would be relatively a short time to make accurate measurements.  The degree of swelling may 
be calculated from the following Equation 
𝐷𝑒𝑔𝑟𝑒𝑒 𝑜𝑓 𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 =
𝑊𝑡−𝑊0
𝑊𝑡
        [5] 
Where Wt denotes the final weight, W0 depicts the initial weight. 
5.2.6. In vitro disintegration time 
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The disintegration test is one of the important characteristics of FDFs. However, there is no official 
apparatus to determine the disintegration of films accurately. The disintegration time may be 
estimated by two methods: a) the Disintegration Test Apparatus b) petri dish. For the 
Disintegration Test Apparatus, the film is placed in a basket over 2-mm-size mesh with 
disintegration disk on it. The basket is raised and lowered in a solution (typically distilled water) 
at 37C. The time is recorded for each film to disintegrate and pass the residue completely through 
the wire mesh. The estimated disintegration time may become longer than it is, if film residues 
adhere to the mesh, or the immersion liquid gets cloudy. For the petri dish method, the film strip 
(about 4 cm2) is placed in a petri dish (internal diameter of 5 cm), which contains 10 ml of 
simulated saliva. The disintegration time is considered as a time when film starts to 
disintegrate.[92] 
5.2.7. In vitro dissolution studies 
Dissolution testing is carried out for FDFs according to compendial methods.[123] A phosphate 
buffer is utilised with pH of 6.8 [123] or 5.7 (to simulate saliva).[102] The solution temperature 
is maintained at 37 ± 1C, however, the compendial apparatus usually is not suitable for 
measuring the dissolution rate of drug from FDFs. Therefore, Adrover et al. 2015 developed a 
microfluidic device for dissolution studies of FDF.[124] In another approach, Krampe et al. 2016 
modified the compendial paddle apparatus and developed a novel device to simulate the 
conditions in the mouth by adapting the composition of the saliva, the mechanical force of the 
tongue, the saliva volume and saliva flow.[125] 
5.2.8. Fourier infrared transform spectroscopy  
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Fourier Transform Infrared Spectroscopy (FTIR) is conducted on FDFs to allow identifying the 
interaction between drug, plasticizer molecules with the polymer.[12, 126] Hence, an efficient 
plasticizer would show modifications of the polymer peaks.[88]  
5.2.9. Differential scanning calorimetry 
Thermodynamic properties of pure API, polymer, mixtures, filaments and 3D printed films are 
examined using a differential scanning calorimeter (DSC).[11, 12] The DSC analysis helps to 
identify recrystallisation of API or its amorphous state in the film or filament.[12] Furthermore, 
DSC data shows if water is present in the film, which may be identified by the evaporation of water 
from the film. In addition, DSC data provides information whether the API is dispersed at the 
molecular level in the polymer. This is found by alterations in the melting temperature of the 
polymer.[12] 
5.2.10 Palatability  
Palatability is defined as the property of being acceptable to the mouth. This is important for the 
patient compliance. Palatability test is conducted by obtaining suitable ethical approval. Then 
subjects (volunteers) are asked to provide an evaluation of the FDFs by answering questions 
related to taste, comfort and sensation after administration. [88, 114],] The evaluation is done by 
using a scale system, such as score: 0 (very satisfied), 1 (quite satisfied), 2 (not satisfied) and 3 
(not at all satisfied). [114] The parameters for comfort included convenience of administration, 
speed of disintegration and suitability of pharmaceutical form for taking without water.[88] 
Sensation was evaluated by considering residues left in the mouth after administration. E-tongue 
assessment is also performed to evaluate the taste masking effects.[113] 
5.2.11. X-Ray diffraction 
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The crystalline structure of the samples are analyzed typically at ambient temperature using X-ray 
diffractometer, 3 to 70 with 5/min step.[11] The XRD data would indicate whether the drug is 
dispersed in the film as particles (usually XRD data present crystalline structures), or dissolved in 
the polymer (this is identified by the absence of drug crystalline signals).[126]  
5.2.12. Uniformity of Dosage Units  
The uniformity of dosage units can be demonstrated by the Content Uniformity or Weight 
Variation tests. The Content Uniformity test can be conducted on all dosage form units, but the 
Weight Variation test is conducted on certain dosage units, which the API content is greater than 
25 mg. Therefore, part of FDF formulations that contain more than 25 mg of API would be eligible 
for both tests. The aim of Content Uniformity test is to determine that drug dose from one FDF to 
another is consistent. The test is conducted on 10 samples (BP-2019 Appendix XIIC and USP42 
<905>), when active ingredient is less than 25 mg. The amounts of drug in each FDF unit is 
measured by applying a suitable analytical technique such as high performance liquid 
chromatography. According to the BP and USP, if each individual drug content is between 85 per 
cent and 115 per cent of the average content and standard deviation is less than or equal 6%, then 
the preparation complies with the test.  
5.2.13. Uniformity of drug content in each sample  
Fourier transform infrared (FTIR) imaging have been employed to determine the content 
uniformity in each sample of FDF.[92] In this approach, FTIR spectroscopic imaging with Focal 
plane array Detector is used to analyse the spatial distribution of the drug in the FDF. Following 
acquiring chemical images of films by using a microscope with FTIR system (e.g. Bruker, 
Germany); the images are obtained in transflectance mode by placing the film over a white ceramic 
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disk. Images of an area of approximately 300 µm × 300 µm are obtained. The uniformity of drug 
content in each sample is analysed at different locations. The spectra is obtained with a scan in the 
spectral range of 4000–900 cm-1. Then data is analysed using a suitable software such as integrated 
OPUS operation and evaluation software.[92] 
5.2.14 In vivo Evaluation 
FDFs have been evaluated in animal models.[126, 127] In one approach, rats were fasted overnight 
before administration of film. Then, 50 µL aliquot of distilled water was dropped into the rat oral 
cavity under light ether anesthesia and then film preparation (animal dose = 0.087 mg/kg) was 
placed on the tongue. After ensuring disintegration of the film, anesthesia was discontinued. This 
was followed by measuring drug concentration in the animal plasma to determine drug 
pharmacokinetic parameters.[126]  
5.2.15. Film thickness 
The thickness of each film may be determined by using a digital vernier caliper,[12, 102] with an 
accuracy of 2.5 ± 0.5 µm.[102] 
6. Formulations in various stages of the clinical process 
The current clinical trials are shown in Table 1 in relation to FDFs and few oral strips. The 
information was obtained from https://www.clinicaltrials.gov.  
Table 1: FDFs and some oral films at different stages of clinical trials. 
Company Active Ingredient/ 
Formulation 
Condition/Disease Dosage/Form Phase 
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Nicotine Smoking Cessation Nicotine 4 mg 
oral film  
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7. The Barriers for 3DP of FDFs at Industrial Scale  
FDF market will grow to more than $1.3 billion per annum in next few years and 3D printing of 
FDFs may share part of this market. 3DP of FDFs generally has been a solvent-less process, which 
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can be considered as an important advantage. Amongst the methods published in literature, hot 
melt ram extrusion 3D printer and powder based extrusion 3DP appear to have several advantages 
over FDM 3DP. As explained previously, 3D printing technologies have the potential to allow 
patients to be given a personalised regime, which could include multiple active ingredients, either 
as a single blend or potentially as layers in a multi-layer printed tablet, based on their treatment 
needs. There is no unique regulatory  
 




pathway for the approval of 3DP drugs,[128] but there are existing approval pathways that are 
flexible enough to address new technologies, small batches, orphan drugs, expedited approval 
programs, and personalised medicines. Three major risk areas have been identified relating to 3D 
printing of pharmaceuticals.  
 Product liability risk: if a pharmaceutical company licenses its blueprint to pharmacies or 
healthcare providers to print drugs locally, it still needs to consider the potential product 
liability implications and free from printing defects.[129]  
 Counterfeit risk: the proliferation of counterfeit medicines is perhaps the industry’s greatest 
concern with 3D printing. Printers are much more vulnerable to hackers than traditional 
manufacturing processes, and the incredibly short production time magnifies the risk of 
counterfeits.  
  The safety and efficacy of 3D printers: traditional mass-manufacturing facilities are 
subject to oversight from regulatory bodies. However, the FDA/MHRA would be pushed 
to regulate every instance of 3D printing. Therefore determining the safety of products 
developed and responsibility for adverse events are difficult. 
Development of thin films has been ongoing for many years and there are a number of companies 
who are focused exclusively on developments in this field. Companies are continuing to invest in 
technologies which provide alternatives to standard tablet based drug delivery systems. The market 
for thin film products is already well established with a number of products launched on the 
market, some of which have achieved block buster drug status. Market entry for a new technology 
will therefore be harder than it would, when it enters a rapidly growing market sector. 
The current competitors have identified a number of clinical areas that benefit from rapid 
oral/buccal delivery, [130, 131] and Table 1 presents part of recent clinical trials. It may be difficult 
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to identify additional pharmaceutical agents that have not already been taken to market using 
existing FDF/ODT technologies. Alongside FDF technology there are a number of similar 
techniques for formulating drugs for rapid buccal drug delivery such as fast dissolving tablets. 
Some pharmaceutical agents have been formulated as both FDFs and oral dispersing tablets, which 
means clinicians already have a choice of products to use in the clinic. 
Typically, partnerships with pharmaceutical companies are used as a route to market, with the two 
partner companies bringing different areas of expertise to product development. 
Commercialisation would also require a robust patent strategy to ensure that other operators in this 
sector would not find a way to circumvent the patent. As the concept of printing 3D 
pharmaceuticals is already well profiled and in the public domain, any patent in the area would 
need to be able to focus on unique characteristics of the organisational 3D printing process. 
New market entrants will need to have clearly defined advantages over existing technologies to be 
able to attract funding for product development and finance clinical trials of this new 
technology.[132] The advantages of using 3D printing for the production of medicines primarily 
is focused on the ability to produce customised products for patients. This offers greater flexibility, 
but creates a number of regulatory and security hurdles to ensure that patient safety is not 
compromised. The role of personalised 3D printing within pharmaceutical industry remains 
unclear at the moment and its uptake will depend heavily on whether the regulatory and security 
hurdles can be overcome. Therefore, a recent work has started to address this issue.[44] Based on 
our experience, personalisation of 3DP FDFs would be challenging at pharmacies. This is due to 
the maintenance issues of 3D printers, which after a while would require spare parts; and whether 
these would be available by considering fast changing of 3DP market. While personalised 3D 
printing of dosage forms overcomes the regulatory and security hurdles, nothing is stopping to use 
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of 3D printing in pharmaceutical companies for mass production of FDFs. To achieve this target, 
3DP of FDFs should clearly present advantages over well-established conventional methods of 
producing FDFs. 
7.1. Process Analytical Technology 
Process Analytical Technology (PAT) is considered a system for designing, analysing and 
controlling pharmaceutical manufacturing processes through measurements of critical quality and 
performance attributes. These are applied to both raw and processed materials to ensure final 
product quality. The aim is to build quality in to the product, rather than just testing the product at 
the final stage. Spectroscopic tools including near infrared (NIR) and Raman spectroscopy have 
been shown to be capable of monitoring tablet critical quality attributes (CQAs), namely drug 
content.[133, 134] Trenfield  et al 2018 showed the application of portable near infrared 
spectroscopy and Raman confocal microscopy as PAT tools for 3D printed drug products.[56] 
Furthermore, Raman spectroscopy and Raman chemical imaging were applied to visualise drug 
distribution within a 2D inkjet printed formulations and quantify drug content.[135]  Similarly, 
Vakili et al. 2017 applied a handheld NIR spectrometer to quantify the content of prednisolone 
and levothyroxine in orodispersible films.[136] These studies present methods that have been 
developed to implement PAT for the production 3DP FDFs. In addition, NIR has been applied to 
predict tablet hardness;[137] and an in-line pH monitoring system combined with in-line particle 
size monitoring was employed to predict disintegration of tablets, as part of PAT.[138] Further 
studies are required to identify suitable PAT technique to predict tensile strength and disintegration 




FDM 3DP and hot melt ram extrusion 3D printer have been applied to the formulation of FDFs. 
In addition, inkjet method has been employed to deposit APIs on edible films. Although the 
disintegration time of 3DP FDFs is less than 3 minutes, which complies with pharmacopeia 
specifications, the disintegration time of films made by solvent casting method is much shorter 
(usually within 20 seconds). FDFs usually contain taste masking agents, and FDM 3DP has made 
this feasible. Large-scale production of FDFs is still challenging by using additive manufacturing 
techniques, although recent progress shows promise. The commercial feasibility of the Spirtam 
3DP tablet and FDA approval in August 2015 indicate the potential for commercial feasibility of 
FDFs by additive manufacturing. It should be noted that FDA encourages advanced 
manufacturing, as this can improve drug quality, address shortages of medicines, and increase 
speed of reaching marketable products. In this regard, FDA’s Additive Manufacturing of Medical 
Products (AMMP) core research facility is a multi-centre collaboration. It expands Centre-specific 
resources and accommodates high-end, industry-grade 3D printing equipment, software, and 
expertise that can be used across the Agency to perform cutting-edge regulatory research with this 
advanced technology. 
Applying additive manufacturing could be cost effective in the production of FDFs, in particular 
compared to manufacturing of FDFs by solvent casting method. This is because FDM 3DP and 
hot melt ram extrusion 3D printer do not require using solvents in the manufacture of FDFs. This 
also could improve the safety profile of FDFs by reducing the solvent residues. The production 
time could be faster by using the additive manufacturing compared to the preparation of FDFs by 
the solvent casting method, as there is no need for delays due to evaporation of solvents. It remains 
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to be determined whether 3DP of FDFs can be beneficial from early stages of FDF formulation 
development.  
9. Future Directions 
Simplifying the manufacturing process of 3DP FDFs will be an important future direction. As 
current FDM techniques require the usage of filaments; producing filaments with the desired 
smoothness and mechanical strength brings extra challenge for 3DP of FDFs. Inkjet technique 
utilising molten wax and hot melt ram extrusion 3D printer are additive manufacturing processes 
that do not require the use of filaments. Therefore, further developments of these techniques appear 
desirable. Also, taste-masking agents should be included in future formulations developed by 
novel additive manufacturing techniques. Hot melt ram extrusion 3D printing is an example of 
direct ink writing printing methods,[103] however, pneumatic or screw-fed direct methods [63] 
could be investigated to produce formulations that contain suspensions or to eliminate the piston 
in the printing instrument. The screw-fed direct ink writing method provides the opportunity of 
continuous FDF production. Reducing the printing temperature in 3D FDM would be another 
target to be achieved to ensure stability of the active ingredient or taste masking agents during the 
production process. Developing multi-nozzle 3D printers, where all nozzles print at the same time, 
would help mass production 3DP FDFs. In addition, 3DP of FDF rollstock may help integration 
of 3DP of FDF into current manufacturing process. This means the production of FDF roll by 3DP, 
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